CONSIDERATIONS TO KNOW ABOUT ABBV-744 BRD4 INHIBITOR CANCER THERAPY EFFICACY

In Segment A, contributors will get diverse doses and schedules of oral ABBV-744 tablet to identify Risk-free dosing regimen. Additional contributors are going to be enrolled for the recognized monotherapy dosign program. In Section B, members will obtain oral ruxolitinib and ABBV-744 will be specified as "insert-on" therapy. In Segment C, members